Semax

Peptide

Compounding status of Semax — FDA 503A bulks-list standing, PCAC review history, and state overlays. Each entry links to its source; entries marked reported rest on trade-press coverage until the FDA primary record posts.

Current federal standing

Under review — not compoundable

as of Apr 16, 2026

We do not sell, source, or supply Semax. This is a monitoring record from public government sources — not a product, and not advice.

Federal history

Apr 16, 2026PCAC reviewFederal
Under PCAC review
Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
Note: FDA is not bound by PCAC recommendations. Category 1 placement — the event that would permit 503A compounding — requires notice-and-comment rulemaking, commonly 8–12 months.
2026-07361 · primary source ↗

State overlays

No state-specific position on Semax tracked yet. State boards hold independent authority; legislation is monitored via LegiScan and board positions are added as they are verified.

Track Semax changes

Get the free weekly Brief — FDA and state moves on peptide & GLP-1 compounding, with the source and the date. Members are alerted for their states as soon as a change is published.

Get the free Brief →

← All substances · Informational monitoring from public government sources — not legal or medical advice. No efficacy claims.